US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Imbruvica (ibrutinib) for an expanded first-line mantle cell lymphoma (MCL) indication. The treatment combines ibrutinib with R-CHOP, followed by ibrutinib monotherapy, targeting previously untreated adult MCL patients eligible for autologous stem cell transplantation (ASCT).
Drug Mechanism and Development
Ibrutinib, an oral therapy taken once daily, inhibits Bruton’s tyrosine kinase (BTK), which is crucial for the survival of B-cells. Jointly developed by J&J and Pharmacyclics LLC (an AbbVie company), it helps remove abnormal B-cells and suppress their proliferation.
Global Impact
Registered in over 100 countries and having treated over 325,000 patients, the CHMP’s positive recommendation further solidifies ibrutinib’s role in oncology.-Fineline Info & Tech
